A Phase 2a, Multi-centre, Randomised, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Pyronaridine as an Add-on Therapy in Adults With Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia
Latest Information Update: 01 Dec 2022
At a glance
- Drugs Pyronaridine (Primary)
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Armaceutica
- 23 Nov 2022 Planned End Date changed from 1 Dec 2023 to 1 Mar 2024.
- 23 Nov 2022 Planned primary completion date changed from 1 Nov 2023 to 1 Feb 2024.
- 23 Nov 2022 Status changed from not yet recruiting to recruiting.